VISIT US IN CHICAGO JUNE 2-4 AT BOOTH 2073!

Dr. Villaflor Discusses Alectinib in ALK+ NSCLC

Victoria Villaflor, MD
Published: Wednesday, Oct 04, 2017



Victoria Villaflor, MD, associate professor of medicine, Robert H. Lurie Comprehensive Cancer Center, discusses alectinib (Alecensa) in patients with ALK-positive non–small cell lung cancer (NSCLC).

The ALEX study of alectinib in patients with ALK-positive NSCLC demonstrated a significant benefit in progression-free survival versus standard-of-care crizotinib (Xalkori).
 


Victoria Villaflor, MD, associate professor of medicine, Robert H. Lurie Comprehensive Cancer Center, discusses alectinib (Alecensa) in patients with ALK-positive non–small cell lung cancer (NSCLC).

The ALEX study of alectinib in patients with ALK-positive NSCLC demonstrated a significant benefit in progression-free survival versus standard-of-care crizotinib (Xalkori).
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Oncology Briefings™: Updates in Novel Therapeutic Options for Lung Neuroendocrine TumorsMay 31, 20181.0
Community Practice Connections™: Working Group to Optimize Outcomes in EGFR-mutated Lung Cancers: Evolving Concepts for Nurses to Facilitate and Improve Patient CareJun 30, 20181.5
Publication Bottom Border
Border Publication
x